Abundant pyroglutamate-modified ABri and ADan peptides in extracellular and vascular amyloid deposits in familial British and Danish dementias

Neurobiology of Aging

Volumn 34, Issue 5, 2013, Pages 1416-1425

  Saul, Anika ^a   Lashley, Tammaryn ^b   Revesz, Tamas ^b   Holton, Janice ^b   Ghiso, Jorge A ^c   Coomaraswamy, Janaky ^d   Wirths, Oliver ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

ABri; ADan; Aggregation; Amyloid; Familial British dementia; Familial Danish dementia; Pyroglutamate; Toxicity; Transgenic mice

Indexed keywords

ABRI PROTEIN; ADAN PROTEIN; AMYLOID BETA PROTEIN; AMYLOID PROTEIN; PYROGLUTAMIC ACID; UNCLASSIFIED DRUG;

ADULT; AGED; AMINO TERMINAL SEQUENCE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ARTICLE; BIOASSAY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CYTOTOXICITY; DEMENTIA; FAMILIAL BRITISH DEMENTIA; FAMILIAL DANISH DEMENTIA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MOLECULAR PATHOLOGY; MOUSE; NEUROPATHOLOGY; NONHUMAN; PRESYNAPTIC MEMBRANE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; SYNAPTIC TRANSMISSION; TRANSGENIC MOUSE;

ADULT; AGED; ANIMALS; BLOOD VESSELS; DEMENTIA; EXTRACELLULAR FLUID; FEMALE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, TRANSGENIC; PYRROLIDONECARBOXYLIC ACID;

EID: 84873443057     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2012.11.014     Document Type: Article

References (40)

1. Alexandru A., Jagla W., Graubner S., Becker A., Bauscher C., Kohlmann S., Sedlmeier R., Raber K.A., Cynis H., Ronicke R., Reymann K.G., Petrasch-Parwez E., Hartlage-Rubsamen M., Waniek A., Rossner S., Schilling S., Osmand A.P., Demuth H.U., von Horsten S. Selective hippocampal neurodegeneration in transgenic mice expressing small amounts of truncated A{beta} is induced by pyroglutamate-A{beta} formation. J. Neurosci. 2011, 31:12790-12801.
2. Benilova I., Karran E., De Strooper B. The toxic Abeta oligomer and Alzheimer's disease: an emperor in need of clothes. Nat. Neurosci. 2012, 15:349-357.
3. Busby W.H., Quackenbush G.E., Humm J., Youngblood W.W., Kizer J.S. An enzyme(s) that converts glutaminyl-peptides into pyroglutamyl-peptides. Presence in pituitary, brain, adrenal medulla, and lymphocytes. J. Biol. Chem. 1987, 262:8532-8536.
4. Casas C., Sergeant N., Itier J.M., Blanchard V., Wirths O., van der Kolk N., Vingtdeux V., van de Steeg E., Ret G., Canton T., Drobecq H., Clark A., Bonici B., Delacourte A., Benavides J., Schmitz C., Tremp G., Bayer T.A., Benoit P., Pradier L. Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model. Am. J. Pathol. 2004, 165:1289-1300.
5. Christensen D.Z., Bayer T.A., Wirths O. Intracellular Abeta triggers neuron loss in the cholinergic system of the APP/PS1KI mouse model of Alzheimer's disease. Neurobiol. Aging 2010, 31:1153-1163.
6. Christensen D.Z., Kraus S.L., Flohr A., Cotel M.C., Wirths O., Bayer T.A. Transient intraneuronal Abeta rather than extracellular plaque pathology correlates with neuron loss in the frontal cortex of APP/PS1KI mice. Acta Neuropathol. 2008, 116:647-655.
7. Coomaraswamy J., Kilger E., Wolfing H., Schafer C., Kaeser S.A., Wegenast-Braun B.M., Hefendehl J.K., Wolburg H., Mazzella M., Ghiso J., Goedert M., Akiyama H., Garcia-Sierra F., Wolfer D.P., Mathews P.M., Jucker M. Modeling familial Danish dementia in mice supports the concept of the amyloid hypothesis of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:7969-7974.
8. D'Arrigo C., Tabaton M., Perico A. N-terminal truncated pyroglutamyl beta amyloid peptide Abetapy3-42 shows a faster aggregation kinetics than the full-length Abeta1-42. Biopolymers 2009, 91:861-873.
9. El-Agnaf O.M., Sheridan J.M., Sidera C., Siligardi G., Hussain R., Haris P.I., Austen B.M. Effect of the disulfide bridge and the C-terminal extension on the oligomerization of the amyloid peptide ABri implicated in familial British dementia. Biochemistry 2001, 40:3449-3457.
10. Ghiso J., Rostagno A., Tomidokoro Y., Lashley T., Bojsen-Moller M., Braendgaard H., Plant G., Holton J., Lal R., Revesz T., Frangione B. Genetic alterations of the BRI2 gene: familial British and Danish dementias. Brain Pathol. 2006, 16:71-79.
11. Gibson G., El-Agnaf O.M., Anwar Z., Sidera C., Isbister A., Austen B.M. Structure and neurotoxicity of novel amyloids derived from the BRI gene. Biochem. Soc. Trans. 2005, 33(Pt 5):1111-1112.
12. Guntert A., Dobeli H., Bohrmann B. High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain. Neuroscience 2006, 143:461-475.
13. Harigaya Y., Saido T.C., Eckman C.B., Prada C.M., Shoji M., Younkin S.G. Amyloid beta protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer's disease brain. Biochem. Biophys. Res. Commun. 2000, 276:422-427.
14. He W., Barrow C.J. The A beta 3-pyroglutamyl and 11-pyroglutamyl peptides found in senile plaque have greater beta-sheet forming and aggregation propensities in vitro than full-length A beta. Biochemistry 1999, 38:10871-10877.
15. Holton J.L., Ghiso J., Lashley T., Rostagno A., Guerin C.J., Gibb G., Houlden H., Ayling H., Martinian L., Anderton B.H., Wood N.W., Vidal R., Plant G., Frangione B., Revesz T. Regional distribution of amyloid-Bri deposition and its association with neurofibrillary degeneration in familial British dementia. Am. J. Pathol. 2001, 158:515-526.
16. Holton J.L., Lashley T., Ghiso J., Braendgaard H., Vidal R., Guerin C.J., Gibb G., Hanger D.P., Rostagno A., Anderton B.H., Strand C., Ayling H., Plant G., Frangione B., Bojsen-Moller M., Revesz T. Familial Danish dementia: a novel form of cerebral amyloidosis associated with deposition of both amyloid-Dan and amyloid-beta. J. Neuropathol. Exp. Neurol. 2002, 61:254-267.
17. Jawhar S., Wirths O., Bayer T.A. Pyroglutamate Abeta - a hatchet man in Alzheimer disease. J. Biol. Chem. 2011, 286:38825-38832.
18. Jawhar S., Wirths O., Schilling S., Graubner S., Demuth H.U., Bayer T.A. Overexpression of glutaminyl cyclase, the enzyme responsible for pyroglutamate abeta formation, induces behavioral deficits, and glutaminyl cyclase knock-out rescues the behavioral phenotype in 5XFAD mice. J. Biol. Chem. 2011, 286:4454-4460.
19. Kim S.H., Creemers J.W., Chu S., Thinakaran G., Sisodia S.S. Proteolytic processing of familial British dementia-associated BRI variants: evidence for enhanced intracellular accumulation of amyloidogenic peptides. J. Biol. Chem. 2002, 277:1872-1877.
20. Kim S.H., Wang R., Gordon D.J., Bass J., Steiner D.F., Lynn D.G., Thinakaran G., Meredith S.C., Sisodia S.S. Furin mediates enhanced production of fibrillogenic ABri peptides in familial British dementia. Nat. Neurosci. 1999, 2:984-988.
21. Kuo Y.M., Webster S., Emmerling M.R., De Lima N., Roher A.E. Irreversible dimerization/tetramerization and post-translational modifications inhibit proteolytic degradation of A beta peptides of Alzheimer's disease. Biochim. Biophys. Acta 1998, 1406:291-298.
22. McLean C.A., Cherny R.A., Fraser F.W., Fuller S.J., Smith M.J., Beyreuther K., Bush A.I., Masters C.L. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 1999, 46:860-866.
23. Mead S., James-Galton M., Revesz T., Doshi R.B., Harwood G., Pan E.L., Ghiso J., Frangione B., Plant G. Familial British dementia with amyloid angiopathy: early clinical, neuropsychological and imaging findings. Brain 2000, 123(Pt 5):975-991.
24. Russo C., Violani E., Salis S., Venezia V., Dolcini V., Damonte G., Benatti U., D'Arrigo C., Patrone E., Carlo P., Schettini G. Pyroglutamate-modified amyloid beta-peptides-AbetaN3(pE)-strongly affect cultured neuron and astrocyte survival. J. Neurochem. 2002, 82:1480-1489.
25. Saido T.C., Iwatsubo T., Mann D.M., Shimada H., Ihara Y., Kawashima S. Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques. Neuron 1995, 14:457-466.
26. Schilling S., Lauber T., Schaupp M., Manhart S., Scheel E., Bohm G., Demuth H.U. On the seeding and oligomerization of pGlu-amyloid peptides (in vitro). Biochemistry 2006, 45:12393-12399.
27. Schilling S., Zeitschel U., Hoffmann T., Heiser U., Francke M., Kehlen A., Holzer M., Hutter-Paier B., Prokesch M., Windisch M., Jagla W., Schlenzig D., Lindner C., Rudolph T., Reuter G., Cynis H., Montag D., Demuth H.U., Rossner S. Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology. Nat. Med. 2008, 14:1106-1111.
28. Schlenzig D., Manhart S., Cinar Y., Kleinschmidt M., Hause G., Willbold D., Funke S.A., Schilling S., Demuth H.U. Pyroglutamate formation influences solubility and amyloidogenicity of amyloid peptides. Biochemistry 2009, 48:7072-7078.
29. Steiner D.F. The proprotein convertases. Curr. Opin. Chem. Biol. 1998, 2:31-39.
30. Sykes P.A., Watson S.J., Temple J.S., Bateman R.C. Evidence for tissue-specific forms of glutaminyl cyclase. FEBS Lett. 1999, 455:159-161.
31. Takahashi R.H., Almeida C.G., Kearney P.F., Yu F., Lin M.T., Milner T.A., Gouras G.K. Oligomerization of Alzheimer's beta-amyloid within processes and synapses of cultured neurons and brain. J. Neurosci. 2004, 24:3592-3599.
32. Tomidokoro Y., Lashley T., Rostagno A., Neubert T.A., Bojsen-Moller M., Braendgaard H., Plant G., Holton J., Frangione B., Revesz T., Ghiso J. Familial Danish dementia: co-existence of Danish and Alzheimer amyloid subunits (ADan and Abeta) in the absence of compact plaques. J. Biol. Chem. 2005, 280:36883-36894.
33. Tomidokoro Y., Tamaoka A., Holton J.L., Lashley T., Frangione B., Revesz T., Rostagno A., Ghiso J. Pyroglutamate formation at the N-termini of ABri molecules in familial British dementia is not restricted to the central nervous system. Hirosaki Igaku 2010, 61:S262-S269.
34. Vidal R., Frangione B., Rostagno A., Mead S., Revesz T., Plant G., Ghiso J. A stop-codon mutation in the BRI gene associated with familial British dementia. Nature 1999, 399:776-781.
35. Vidal R., Revesz T., Rostagno A., Kim E., Holton J.L., Bek T., Bojsen-Moller M., Braendgaard H., Plant G., Ghiso J., Frangione B. A decamer duplication in the 3' region of the BRI gene originates an amyloid peptide that is associated with dementia in a Danish kindred. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:4920-4925.
36. Walsh D.M., Tseng B.P., Rydel R.E., Podlisny M.B., Selkoe D.J. The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochemistry 2000, 39:10831-10839.
37. Wirths O., Bethge T., Marcello A., Harmeier A., Jawhar S., Lucassen P.J., Multhaup G., Brody D.L., Esparza T., Ingelsson M., Kalimo H., Lannfelt L., Bayer T.A. Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases. J. Neural. Transm. 2010, 117:85-96.
38. Wirths O., Breyhan H., Cynis H., Schilling S., Demuth H.U., Bayer T.A. Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model. Acta Neuropathol. 2009, 118:487-496.
39. Wirths O., Erck C., Martens H., Harmeier A., Geumann C., Jawhar S., Kumar S., Multhaup G., Walter J., Ingelsson M., Degerman-Gunnarsson M., Kalimo H., Huitinga I., Lannfelt L., Bayer T.A. Identification of low molecular weight pyroglutamate A{beta} oligomers in Alzheimer disease: a novel tool for therapy and diagnosis. J. Biol. Chem. 2010, 285:41517-41524.
40. Wirths O., Multhaup G., Czech C., Feldmann N., Blanchard V., Tremp G., Beyreuther K., Pradier L., Bayer T.A. Intraneuronal APP/A beta trafficking and plaque formation in beta-amyloid precursor protein and presenilin-1 transgenic mice. Brain Pathol. 2002, 12:275-286.